Skip to content

Study · Not a test of the peptide alone · 2003

3 results

Evidence for a role for vasoactive intestinal peptide in active vasodilatation in the cutaneous vasculature of humans.

Bennett LA, Johnson JM, Stephens DP, Saad AR, Kellogg DL Jr

The Journal of physiology7 Jul 2003Cited by 87 (Europe PMC)

PMID12847205 (opens in a new tab)DOI10.1113/jphysiol.2003.042135 (opens in a new tab)PepBankPUB-12847205
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone3

In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

  1. 01HumanNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneNon-randomized trialMechanism

    In human skin, all sites treated with the antagonist VIP(10-28) showed attenuated dilation in response to VIP.

    In plain wordsIn human skin, the VIP blocker VIP(10-28) reduced the vessel widening caused by VIP at every tested concentration.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    DecreaseVIP-induced dilation with VIP(10-28) at three concentrations
    Study

    n: not reported in source

    Comparator
    Ringer solution control site
    Outcome group
    Vascular function · Cardiovascular

    Source sentences

    Summary
    All VIP(10-28)-treated sites displayed an attenuated dilatation in response to the VIP.
    1 context sentence
    Summary · context
    (1) We administered VIP by intradermal microdialysis to four discrete areas of skin in the presence of different levels of the VIP receptor antagonist, VIP(10-28), also delivered by microdialysis.

    In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

  2. 02HumanNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneNon-randomized trialMechanism

    In human skin, the greatest attenuation of VIP-induced dilation occurred at the site that received 214 microM VIP(10-28).

    In plain wordsIn human skin, the highest tested dose of the VIP blocker VIP(10-28) reduced VIP-induced vessel widening the most.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    DecreaseVIP-induced dilation with 214 microM VIP(10-28)
    Study

    n: not reported in source

    Comparator
    Other VIP(10-28) concentrations and control
    Outcome group
    Vascular function · Cardiovascular

    Source sentences

    Summary
    The greatest attenuation was observed at the site that received 214 microM VIP(10-28) (P < 0.01).
    1 context sentence
    Summary · context
    (1) We administered VIP by intradermal microdialysis to four discrete areas of skin in the presence of different levels of the VIP receptor antagonist, VIP(10-28), also delivered by microdialysis.

    In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

  3. 03HumanNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneNon-randomized trialMechanism

    In heated human skin, VIP(10-28), alone or with atropine, attenuated the increase in cutaneous vascular conductance during heat stress.

    In plain wordsIn human skin during heating, the VIP blocker VIP(10-28), alone or with atropine, reduced the increase in blood vessel widening.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    DecreaseIncrease in cutaneous vascular conductance during heat stress
    Study

    n: not reported in source

    Comparator
    Ringer solution control site
    Outcome group
    Vascular function · Cardiovascular

    Source sentences

    Summary
    VIP(10-28), alone or in combination with atropine, attenuated the increase in CVC during heat stress
    2 context sentences
    Summary · context
    After 1 h of VIP(10-28) treatment, individuals underwent 45-60 min of whole-body heating (Tsk to 38.5 degrees C).
    Summary · context
    (1) We administered VIP by intradermal microdialysis to four discrete areas of skin in the presence of different levels of the VIP receptor antagonist, VIP(10-28), also delivered by microdialysis.

    In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 19:08 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 12:41 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.